We are live on ! Find out more
BGLC icon

BioNexus Gene Lab
BGLC

3 hedge funds and large institutions have $30.3K invested in BioNexus Gene Lab in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.06% → 0.04% (-0.02%)

25% less funds holding

Funds holding: 4 → 3 (-1)

57% less capital invested

Capital invested by funds: $70.7K → $30.3K (-$40.4K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$11K
2
UBS Group
UBS Group
Switzerland
-$5.94K
3
HF
HRT Financial
New York
-$4.06K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$13K -$11K -1,967 -42%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$11.3K – – –
HF
3
HRT Financial
New York
$6K -$4.06K -723 -33%
UBS Group
4
UBS Group
Switzerland
– -$5.94K -842 Closed

BGLC Hedge Fund Activity: Q2 2024 in Review

3 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q2 2024, worth a combined $30.3K — down 57% from $70.7K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BGLC and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest seller was Virtu Financial, cutting an estimated $11K.

  • 3 institutional investors held BioNexus Gene Lab (BGLC) as of Q2 2024, down from 4 in Q1 2024.
  • Funds reported $30.3K of BioNexus Gene Lab stock for Q2 2024, down 57% quarter-over-quarter.
  • 0 funds opened new BioNexus Gene Lab positions in Q2 2024 and 1 closed out, a net change of -1 holder.
  • The largest BioNexus Gene Lab seller in Q2 2024 was Virtu Financial, an estimated $11K sold.

Based on aggregated 13F filings for Q2 2024.